By Associate Professor Hao-Wen Sim

Conference Abstracts

Gedye C; Cuff KE; Lau PKH; Dowling AJ; Lwin Z; Cooper AJ; Harrup RA; Dunlop TN; Wheeler H; Briscoe KP; Hovey EJ; Sim H-W; Barnes EH; Koh E-S; Simes J; Gan HK; Hall M; Kong BY; Halkett GKB; Jeffree RL; Consortium M, 2026, 'MAGMA: Multi-arm glioblastoma Australasia phase 3 trial.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 44, pp. 2004 - 2004, http://dx.doi.org/10.1200/jco.2026.44.16_suppl.2004

Liu J; Cosman R; Childs S; Cohen JE; Rodrigues A; Hansen T; Kiely BE; Chen J; Pala A; Sandhu G; Ho J; Warakulasuriya S; Elgundi D; Sim H-W; Kent R; Martin C; Woodson EM; Chaffer CL; Dear R, 2026, 'Abstract CT043: Androgen receptor inhibition to overcome taxane resistance in AR-positive metastatic TNBC: Interim results of the 4CAST Phase 1b trial', in Cancer Research, American Association for Cancer Research (AACR), Vol. 86, pp. ct043 - ct043, http://dx.doi.org/10.1158/1538-7445.am2026-ct043

Vogel A; Bridgewater JA; Gardini AC; Karachiwala H; Wilmink H; Geboes K; McDermott R; Martin AJM; Sim H-W; Roderburg C; Touchefeu Y; Vidra RA; Hong JY; Klint L; Gharbi H; Geng J; Robert R; Rimassa L; Mercade TM, 2026, '348P Long-term efficacy of ivosidenib in patients with IDH1 mutated cholangiocarcinoma (mIDH1 CCA): Focus on long responders from the phase IIIb ProvIDHe study', in Annals of Oncology, Elsevier, Vol. 37, pp. s128 - s129, http://dx.doi.org/10.1016/j.annonc.2026.05.389

Yuile A; Satgunaseelan L; Alexander KL; Thavaneswaran S; Sim H-W; Zaman A; Powell J; Meng A; Escher C; Wei JQ; Wei G; Lee M; Buckland ME; Kong BY; Kastelan M; Wong M; Wilson I; Bayly A; Varikatt W; Lwin Z; Rodriguez M; Soh HC; Gill A; Zakarya R; Back MF; Pavlakis N; Chan DL; Lee A; Wheeler HR; Hudson AL, 2025, 'PATH-18. Investigating the role of CDKN2A loss in IDH-mutant gliomas: biological insights beyond tumour grading', in Neuro-Oncology, Oxford University Press (OUP), Vol. 27, pp. v243 - v244, http://dx.doi.org/10.1093/neuonc/noaf201.0970

Southi N; Sim H-W; Grady J; Satgunaseelan L; Huang M; Kansara M; Yuile A; Zaman A; Lin F; Wheeler H; Hudson A; Ballinger ML; Thomas DM; Thavaneswaran S, 2025, 'PATH-52. Understanding the prevalence ofMTAP andCDKN2A/B deletion in gliomas by next generation sequencing', in Neuro-Oncology, Oxford University Press (OUP), Vol. 27, pp. v252 - v252, http://dx.doi.org/10.1093/neuonc/noaf201.1004

Thavaneswaran S; Koh E-S; Sim H-W; Ballinger ML; Thomas DM; Barnes EH; Kong B; O’Callaghan C; Pitz M; Hawkins C; Roberge D; Pallimulla S; Ralston L; Yip S; Day BW; Verhaak RGW; Buckland M; Amanuel B; Simes J; De Lourenco RA; Solano NZ; Calder R; Adda L; Ahern E; Cooper A; Dowling A; Harrup R; Kichenadasse G; Lau B; Lynam J; Lwin Z; Wheeler H; Whittle JR; Norrie A; Harrison R; Mason WP; de Robles P; Maddula M; Gan HK, 2025, 'TIP-16. Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS (LUMOS2) study', in Neuro-Oncology, Oxford University Press (OUP), Vol. 27, pp. v423 - v424, http://dx.doi.org/10.1093/neuonc/noaf201.1676

Gardini AC; Wilmink H; Bridgewater JA; Mercade TM; Sim H-W; Verslype C; Roderburg C; Touchefeu Y; McDermott R; Kordes M; Lee C-K; Vogel A; Kzhdryan HGK; Vidra RA; Rumpold H; Sullivan A; Gharbi H; Minguez VM; Robert R; Rimassa L, 2025, '107eP Safety of ivosidenib in patients with mIDH1 CCA: Updated results from the phase IIIb ProvIDHe study', in Annals of Oncology, Elsevier, Vol. 36, pp. s244, http://dx.doi.org/10.1016/j.annonc.2025.08.540

Pitiyarachchi O; Sim H-W; OConnell R; Lanceley A; Lobbedez FJ; Hilpert F; Sehouli J; Pignata S; Berton-Rigaud D; Kaminsky-Forrett M-C; Okamoto A; Yoshida Y; Donnellan P; Oza AM; Lindemann K; Berek JS; Ledermann JA; Friedlander ML, 2025, '1131P Upgrading the performance of ECOG performance status in recurrent ovarian cancer (ECOG+)', in Annals of Oncology, Elsevier, Vol. 36, pp. s752, http://dx.doi.org/10.1016/j.annonc.2025.08.1767

Chung S; Holst J; Teng C; Cooper A; Wei J; Koh E-S; Yeo N; Sim H-W; Killen AJ; Gayaman R; Lynch S; Mandala A; Murray C; Joshi S; Mcdonald K; Ashley D; Desjardins A; Sampson J; Archer G; Lemech C; Hovey E, 2025, 'INTERROGATE-GBM Phase I trial: Immunotherapy peptide vaccine targeting cytomegalovirus (CMV) antigens in glioblastoma', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 27, pp. v425 - v425, http://dx.doi.org/10.1093/neuonc/noaf201.1679

Vaios E; Wimberly C; Sim H-W; Barnes L; Koh E-S; Yip S; Hall M; Ashley D; Sulman E; Reitman Z; Walsh K; Khasraw M, 2024, 'GENOME-WIDE DNA METHYLATION PATTERNS IN PERIPHERAL BLOOD OF PATIENTS WITH GLIOBLASTOMA ENROLLED ON THE PHASE II VERTU TRIAL', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, TX, Houston, Vol. 26, presented at 29th Annual Meeting and Education Day of the Society-for-Neuro-Oncology (SNO), TX, Houston, 21 November 2024 - 24 November 2024, http://dx.doi.org/10.1093/neuonc/noae165.0138

Hall A; Crumbaker M; Pham J; Liu J; Sim HW; Joshua AM, 2024, 'A meta-analysis of overall survival and response in metastatic adrenocortical carcinoma: A review of 23 prospective trials of 880 patients.', in Journal of Clinical Oncology, Vol. 42, pp. 4 - 4, http://dx.doi.org/10.1200/JCO.2024.42.4_suppl.4

Klingberg D; Bae S; Zhou D; Sim H-W; Cai R; Anazodo A; Grimison PS; Lewis CR; Lee YC, 2022, 'Dose intensity and outcomes of VDC/IE chemotherapy for adolescent and adult patients with Ewing’s family sarcoma.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 11570 - 11570, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.11570

Sim HW; Mcdonald KL; Lwin Z; Barnes EH; Rosenthal M; Foote MC; Koh ES; Back M; Wheeler H; Sulman EP; Buckland ME; Fisher L; Leonard R; Hall M; Ashley DM; Yip S; Simes J; Khasraw M, 2021, 'A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: The VERTU study', in Neuro Oncology, Vol. 23, pp. 1736 - 1749, http://dx.doi.org/10.1093/neuonc/noab111

Agar M; Nowak A; Hovey E; Barnes E; Simes J; Vardy J; Wheeler H; Leonard R; Hall M; Tim E; Spyridopoulos D; Sim H-W; Lwin Z; Dowling A; Harrup R; Jennens R; Kichenadasse G; Dunlop T; Gzell C; Koh E-S, 2020, 'PHASE II RANDOMISED PLACEBO-CONTROLLED DOUBLE-BLIND STUDY OF ACETAZOLAMIDE VERSUS PLACEBO FOR CEREBRAL OEDEMA IN RECURRENT AND/OR PROGRESSIVE HIGH-GRADE GLIOMA REQUIRING TREATMENT WITH DEXAMETHASONE', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, ELECTR NETWORK, Vol. 22, pp. 179 - 180, presented at 25th Virtual Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO), ELECTR NETWORK, 19 November 2020 - 21 November 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000590061300749&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Khasraw M; McDonald KL; Rosenthal M; Lwin Z; Ashley DM; Wheeler H; Barnes E; Foote MC; Koh E-S; Sulman EP; Back M; Buckland M; Sim H-W; Fisher L; Leonard R; Hall M; Yip S; Simes J, 2019, 'A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 37, pp. 2011 - 2011, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.2011

Back to profile page